Comment on: Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study

被引：0
|
作者：
Nuggehally R. Srinivas
机构：
[1] Zydus Research Centre,
[2] a Division of Cadila Healthcare Ltd,undefined
[3] Jubilant Life Sciences,undefined
[4] Innovation and Technology,undefined
来源：
Clinical Drug Investigation | 2019年 / 39卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：105 / 107
页数：2
相关论文
共 50 条
  • [31] First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects
    Chen, Rui
    Guan, Xiaoduo
    Hu, Pei
    Dong, Yanli
    Zhu, Yi
    Zhang, Tengfei
    Zou, Jianjun
    Zhang, Shuyang
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [32] The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652 in First-in-Human and Ascending Multiple Oral Dose Studies in Healthy Subjects
    Masaomi Takizawa
    Dirk Cerneus
    Ingrid Michon
    Sanne Rijnders
    Desiree van der Heide
    John Meijer
    Matthias Stoelzel
    Yuichiro Sato
    Advances in Therapy, 2020, 37 : 3878 - 3900
  • [33] The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652 in First-in-Human and Ascending Multiple Oral Dose Studies in Healthy Subjects
    Takizawa, Masaomi
    Cerneus, Dirk
    Michon, Ingrid
    Rijnders, Sanne
    van der Heide, Desiree
    Meijer, John
    Stoelzel, Matthias
    Sato, Yuichiro
    ADVANCES IN THERAPY, 2020, 37 (09) : 3878 - 3900
  • [34] A randomized phase I study of the safety and pharmacokinetics of BI 1291583 in healthy Japanese male subjects
    Tadayasu, Yusuke
    Sarubbi, Donald
    Furuichi, Takumi
    Eleftheraki, Anastasia
    Nakamura, Shuhei
    Sauter, Wiebke
    Hanada, Ryuzo
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 91 (01) : 199 - 209
  • [35] Pharmacokinetics and pharmacodynamics of mibavademab (a leptin receptor agonist): Results from a first-in-human phase I study
    Gewitz, Andrew
    Mendell, Jeanne
    Wang, Yuhuan
    Harris, Charles
    Olenchock, Benjamin A.
    Podgrabinska, Simona
    Zheng, Wenjun
    Zhao, An
    Pan, Hao
    Vanhoutte, Frederic
    Davis, John D.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (04):
  • [36] WS016, a novel potassium binder: safety, tolerability and pharmacodynamics in first-in-human phase 1 healthy volunteer study
    Zhang, Faming
    Song, Aiyun
    Fu, Min
    Zhou, Youcheng
    Hu, Minglong
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I1149 - I1151
  • [37] WS016, a novel potassium binder: safety, tolerability and pharmacodynamics in first-in-human phase 1 healthy volunteer study
    Zhang, Faming
    Song, Aiyun
    Fu, Min
    Zhou, Youcheng
    Hu, Minglong
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [38] First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjects
    Yang, Jing
    Lickliter, Jason D.
    Hillson, Jan L.
    Means, Gary D.
    Sanderson, Russell J.
    Carley, Kay
    Tercero, Almudena
    Manjarrez, Kristi L.
    Wiley, Jennifer R.
    Peng, Stanford L.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (04): : 1314 - 1326
  • [39] Pharmacokinetics, Pharmacodynamics, and Safety of HD-6277, a Selective Agonist of G-Protein-Coupled Receptor 40, in Healthy Subjects as a First-in-Human Study
    Kim, Ki-Hwan
    Kim, Pan-Kyung
    Yang, Hye-Jung
    DIABETES, 2019, 68
  • [40] Safety, tolerability and pharmacokinetics and pharmacodynamics of HL2351, a novel hybrid fc-fused interleukin-1 receptor antagonist, in healthy subjects: A first-in-human study
    Oh, Jaeseong
    Huh, Ki Young
    Cho, Young-Gyu
    Cha, Ji-Eun
    Kim, Se-Jin
    Yoon, Seo Hyun
    Park, Sung Sup
    Yoon, Hyunyee
    Lee, Jieon
    Lee, Howard
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (02) : 372 - 379
12345